Incidence of organ failure, local complications, and deaths in the two groups
| Complications | Placebo group | Lexipafant group |
|---|---|---|
| Organ failure | ||
| On admission | 59 (43%) | 67 (45%) |
| Day 3 | 46 (33%) | 40 (27%) |
| Day 7 | 36 (26%) | 29 (20%) |
| Overall | 80/138 (58%) | 85/148 (57%) |
| Local complications | ||
| Pseudocyst | 19 (14%) | 8 (5%)3-a |
| Necrosis | 29 (21%) | 23 (16%) |
| Abscess | 6 (4%) | 5 (3%) |
| Overall | 41/138 (30%) | 30/148 (20%)3-b |
| Systemic sepsis | 13/138 (9%) | 4/148 (3%)3-c |
| Deaths | ||
| All attributable deaths | 21/136 (15%) | 14/147 (10%) |
| Attributable deaths in patients treated ⩽48 h | 17/95 (18%) | 8/104 (8%)3-d |